A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
Condition(s):T-Cell LymphomaLast Updated:September 18, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):T-Cell LymphomaLast Updated:September 18, 2023Active, not recruiting
Condition(s):Relapsed/Refractory Classical Hodgkin LymphomaLast Updated:February 17, 2022Recruiting
Condition(s):Hodgkin LymphomaLast Updated:December 1, 2023Recruiting
Condition(s):Relapsed or Refractory EBV-and CD30-positive LymphomasLast Updated:November 4, 2019Completed
Condition(s):Lymphatic DiseasesLast Updated:March 22, 2022Completed
Condition(s):Germ Cell CancerLast Updated:February 7, 2018Completed
Condition(s):Non-Hodgkin LymphomaLast Updated:September 6, 2018Completed
Condition(s):Hodgkin DiseaseLast Updated:May 11, 2018Completed
Condition(s):Hodgkin LymphomaLast Updated:April 9, 2021Completed
Condition(s):Hodgkin’s LymphomaLast Updated:July 21, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.